AbbVie Receives U.S. FDA Approval of MAVYRET glecaprevir/pibrentasvir for the Treatment of Chronic Hepatitis C in All Major Genotypes GT 1-6 in as...

Press/Media: Press / Media

PeriodAug 14 2017

Media coverage

2

Media coverage

  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET glecaprevir/pibrentasvir for the Treatment of Chronic Hepatitis C in All Major Genotypes GT 1-6 in as...
    Media name/outletPharmacy Choice
    CountryUnited States
    Date8/14/17
    PersonsFred Poordad
  • Title8/14/17 - AbbVie Receives U.S. FDA Approval of MAVYRET glecaprevir/pibrentasvir for the Treatment of Chronic Hepatitis C in All Major Genotypes GT 1-6 in as...
    Media name/outletPharmacy Choice
    CountryUnited States
    Date8/14/17
    PersonsFred Poordad